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In the peak of the 2009 Q fever outbreak in the Netherlands, we introduced a diagnostic algorithm for
acute Q fever with an enzyme-linked immunosorbent assay for immunoglobulin M antibodies to Coxiella
burnetii phase II antigens (MII screen) as an initial step. Subsequently, an immunofluorescence assay or
PCR was performed depending on the MII screen outcome, date of onset of disease, and inpatient or
outpatient setting. The impact of MII screen on the number of immunofluorescence assays performed and
the contribution of PCR to diagnosis were retrospectively evaluated in 825 patients referred in a 17-day
period. Acute Q fever was diagnosed in 256 patients. The introduction of MII screen reduced the number
of immunofluorescence assays performed by more than 80%. In 103 patients, PCR analysis contributed to
the diagnosis of acute Q fever. Q fever diagnostics were hampered by the fact that for a high number of
patients the date of onset of disease was not provided and the requested follow-up serum samples were not
received.
Q fever is a ubiquitous zoonosis caused by the intracellular
coccobacillus Coxiella burnetii. In 1937, it was first described
in five slaughterhouse workers, two dairy farmers, and one
sewage construction worker in Brisbane, Australia, by Ed-
ward Derrick (1). C. burnetii has an enormous range of hosts
and can infect mammals (primarily sheep, cattle, and goats),
birds, and arthropods, including ticks (2). The bacterium is
shed in urine, feces, and milk and in especially high concen-
trations in placentas and birth fluids from infected animals.
Inhalation of aerosols contaminated with the bacterium can
infect humans (5). However, transmission through consum-
ing contaminated milk and cheese, getting bitten by ticks, or
having sex with an infected person has also been reported.
Infection of humans results in either subclinical seroconver-
sion or a flu-like syndrome with fever, headache, fatigue,
malaise, pneumonia, or hepatitis known as acute Q fever. C.
burnetii can be developed for use in biological warfare and
is considered a potential bioterrorist threat (2).
Since 2007, the south of the Netherlands has been
plagued by a large ongoing community outbreak of Q fever.
From 1978 until 2006, between 1 and 32 Q fever cases were
notified annually, with an average of 17 cases per year (5, 7).
In 2007, 182 cases were notified, followed by 1,000 cases in
2008 and 2,361 cases in 2009. Seven patients were recorded
to have died in 2008 and 2009 as a result of Q fever. The
geographic spread of notified Q fever cases points to mul-
tiple sources and has been linked with high-intensity dairy
goat farming in densely populated areas. Many patients,
however, never had direct contact with animals (2). In-
creased awareness has led to a decrease in the interval
between onset of disease and date of diagnosis from a me-
dian of 77 days in 2007 to 29 days in 2008 and 17 days in
2009 (6).
The Jeroen Bosch Hospital (JBH) in ’s-Hertogenbosch is
in the center of Noord-Brabant, the province hit hardest by
the Q fever explosion. In 2009, the JBH diagnosed more
than 1,300 Q fever cases and over 18,000 requests for Q
fever diagnostics were received, with a maximum of 182
requests on a single day. To cope with the increasing de-
mand for Q fever diagnostics, we implemented a diagnostic
algorithm on 1 May 2009. The aim of this diagnostic algo-
rithm was to provide accurate, fast, cost-effective, and stan-
dardized diagnostics for acute Q fever in an outbreak set-
ting. Before May 2009, the immunofluorescence assay (IFA)
for immunoglobulin M (IgM) and immunoglobulin G (IgG)
antibodies to C. burnetii phase I and phase II antigens had
been the cornerstone of Q fever diagnostics in the JBH.
IFA, however, has disadvantages, as it is time-consuming,
nonautomated, expensive, and subject to interobserver vari-
ability. In addition, the antibody response to C. burnetii
takes time to develop, making serology less suitable for
acute Q fever diagnostics during the first 2 weeks of the
disease (6). Alternative diagnostic approaches incorporated
in the algorithm included an enzyme-linked immunosorbent
assay (ELISA) for IgM antibodies to phase II antigens as a
screening assay and a highly specific real-time PCR, target-
ing IS1111A, for detection of C. burnetii DNA in serum
during the very early stage of the disease. We have previ-
ously shown that this PCR detects C. burnetii DNA in vir-
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tually all sera of seronegative patients with acute Q fever but
rapidly becomes negative when the antibody response de-
velops (6). In this study, we retrospectively examined the
impact of the ELISA on the number of IFA tests performed
and the contribution of PCR to diagnosis with first serum
samples.
MATERIALS AND METHODS
Inclusion criteria. We retrospectively evaluated the outcome of the diag-
nostic algorithm for acute Q fever in patients referred in the peak of the 2009
epidemic from 15 to 31 May with a date of onset of disease 3 months earlier
or without information on the date of onset of disease. Excluded from
analysis were patients with follow-up serum samples referred from 15 to 31
May 2009 for whom initial acute Q fever diagnostics were requested from 1
January to 14 May 2009. However, patients referred for acute Q fever diag-
nostics from 15 to 31 May 2009 for whom an earlier negative outcome had
been obtained in the 2007 or 2008 epidemic before 1 January 2009 were not
excluded.
Diagnostic algorithm. Figure 1 shows the flowchart of the diagnostic algo-
rithm for acute Q fever. All serum samples were initially screened with a
qualitative ELISA for IgM antibodies to phase II antigens (MII screen)
according to the manufacturer’s instructions (Institut VirionSerion GmbH,
FIG. 1. Diagnostic algorithm for acute Q fever in an outbreak setting introduced 1 May 2009 in the Jeroen Bosch Hospital, ’s-
Hertogenbosch, Netherlands. Abbreviations: ELISA MII-screen, enzyme-linked immunosorbent assay for immunoglobulin M antibodies to
Coxiella burnetii phase II antigens; IFA, immunofluorescence assay; IgM-II antibodies, immunoglobulin M antibodies to C. burnetii phase
II antigens; IgG-II antibodies, immunoglobulin G antibodies to C. burnetii phase II antigens; IgG-I antibodies, immunoglobulin G antibodies
to C. burnetii phase I antigens.
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Wu¨rzburg, Germany) on a DSX automated ELISA processing system (Dynex
Technologies, Chantilly, VA).
IFA for IgM and IgG antibodies to phase I and phase II antigens (Focus
Diagnostics, Inc., Cypress, CA) was subsequently performed on all MII screen-
positive and borderline-positive serum samples. IFA was performed according to
the manufacturer’s instructions with the adjustment that titers of 1:32 or greater
were considered positive (instead of titers of 1:16 and greater). When IgM and
IgG antibodies to phase II antigens were detected, the diagnosis of acute Q fever
was made regardless of the presence or absence of IgM and IgG antibodies to
phase I antigens. In cases in which only IgG antibodies to phase II antigens with
or without IgG antibodies to phase I antigens were detected, the diagnosis of past
resolved Q fever was made. When any other combination of antibodies was
found, IFA was considered inconclusive and a PCR was performed on the serum
sample as described previously (6). In the case of a positive PCR, the diagnosis
of acute Q fever was made. If the PCR was negative, a follow-up serum sample
after 14 days was requested.
When the MII screen was negative, PCR was performed on first serum sam-
ples obtained 14 days after the onset of disease and on serum samples referred
by hospital physicians without information on the date of onset of disease. In the
case of a positive PCR, the diagnosis of acute Q fever was made. If the PCR was
negative, a follow-up serum sample after 14 days was requested. In cases in which
serum samples were referred by family physicians without information on the
date of onset of disease, PCR was not performed and a follow-up serum sample
after 14 days was requested. Patients with serum samples obtained 14 days
after onset of disease and a negative MII screen were considered not to have
acute Q fever.
Table 1 lists the six possible outcomes of acute Q fever diagnostics in the
diagnostic algorithm: (i) acute Q fever, (ii) past resolved Q fever, (iii) no acute
Q fever, (iv) cross-reactivity (false-positive MII screen not confirmed by addi-
tional tests in first or follow-up serum samples), (v) inconclusive outcome (non-
compliance with the request to refer a follow-up serum sample), and (vi) incon-
sistency with the diagnostic algorithm (nonadherence to the flowchart of the
diagnostic algorithm).
Additional PCR analysis. The outcome of Q fever diagnostics could be
hampered by noncompliance with the request to refer follow-up serum sam-
ples leading to an inconclusive outcome. This may lead to underdiagnosis of
acute Q fever, especially in the group of patients referred by family physicians
without information on the date of onset of disease and a negative MII
screen, in which case the diagnostic algorithm does not allow for PCR anal-
ysis. In the context of this evaluation, serum samples from this particular
group of patients were retrospectively submitted to additional PCR analysis.
Statistical analysis. The Mann-Whitney U test was used to compare the
numbers of days from the onset of disease to acquisition of the first serum
sample in patients with acute Q fever and either a positive or borderline-
positive MII screen or a negative MII screen. Significance was designated at
P values of 0.05. The test was performed with SPSS 18 software for Win-
dows (SPSS Inc., Chicago, IL).
RESULTS
Study population. Using the laboratory information sys-
tem, 825 patients (421 [51.0%] males and 404 [49.0%] fe-
males) were identified who had been referred for acute Q
fever diagnostics in the 2009 epidemic from 15 to 31 May
and met the inclusion criteria. Hospital physicians referred
143 (17.3%) patients, while the other 682 (82.7%) patients
had been referred by family physicians. The date of onset of
disease was provided for 32/143 (22.4%) referrals from hos-
pital physicians and 396/682 (58.1%) referrals from family
physicians.
Outcome of diagnostic algorithm. The outcome of acute Q
fever diagnostics is presented in Table 2. The diagnosis of
acute Q fever was made in 256/825 (31.0%) patients (161/256
[62.9%] males and 95/256 [37.1%] females), including 11 cases
where this diagnosis was inconsistent with the diagnostic algo-
rithm.
A positive or borderline-positive MII screen in the first
TABLE 1. Outcomes of the diagnostic algorithm for acute Q fever in an outbreak setting and definitions
Outcome in the diagnostic algorithm Definition
Acute Q fever ...................................................................Presence of IgM and IgG antibodies to phase II antigens with or without IgM and IgG
antibodies to phase I antigens or PCR positivity
Past resolved Q fever.......................................................Presence of IgG antibodies to phase II antigens with or without IgG antibodies to phase
I antigens in the absence of IgM antibodies
No acute Q fever..............................................................Absence of a serologic response in serum samples obtained 14 days after onset of
disease
Cross-reactivity .................................................................Presence of false-positive IgM antibodies to phase II antigens detected by ELISA but not
confirmed by additional tests in first or follow-up serum samples
Inconclusive outcome.......................................................Noncompliance with the request to refer a follow-up serum sample
Inconsistency with the diagnostic algorithm .................Nonadherence to the flowchart of the diagnostic algorithm
TABLE 2. Outcome of acute Q fever diagnostics according to a diagnostic algorithm in 825 patients referred from 15 to 31 May 2009
Status
No. of samples with definitive outcome
Relative outcome
overall (%)In first
serum sample
In follow-up
serum sample Overall
Acute Q fever 190 55 245 29.7
Past resolved Q fever 2 1 3 0.4
No acute Q fever 116 129 245 29.7
Cross-reactivity 0 4 4 0.5
Inconclusive outcome 299 2 301 36.5
Inconsistency with the diagnostic algorithm
Acute Q fever 7 4 11
No acute Q fever 5 4 9
Cross-reactivity 0 2 2
Inconclusive outcome 5 0 5
Total with inconsistent result 17 10 27 3.3
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serum sample was obtained in 143/825 (17.3%) and 13/825
(1.6%) of patients, respectively. Subsequent IFA on these
serum samples confirmed the diagnosis of acute Q fever in
94 patients. In the other 62 patients, IFA was either indic-
ative of past resolved Q fever (n  2) or inconclusive (n 
60). Subsequent PCR on the 60 serum samples with incon-
clusive IFA confirmed the diagnosis of acute Q fever in
another 11 patients. Thus, in 49 patients with a positive MII
screen in the first serum sample no conclusive outcome
could be made. Therefore, a follow-up serum sample was
requested, which was received from 31/49 patients. Sero-
logic analysis of these follow-up serum samples yielded the
diagnosis of acute Q fever in 25 patients and indicated
cross-reactivity in 6 patients. Q fever diagnostics were con-
sidered inconclusive in the 18 patients for whom the re-
quested follow-up serum sample was not received.
A negative MII screen in the first serum sample was
obtained in 669/825 (81.1%) patients. As a result, the num-
ber of IFA tests performed on first serum samples was
reduced for more than 80% of patients. Subsequently, PCR
was performed on 230 MII screen-negative first serum sam-
ples obtained 14 days after the onset of disease and 94 MII
screen-negative first serum samples referred by hospital
physicians without information on the date of onset of dis-
ease. In these groups, PCR yielded the diagnosis of acute Q
fever in 75/230 (32.7%) and 17/94 (18.1%) patients, respec-
tively. In 454 patients with a negative MII screen in the first
serum sample, a follow-up serum sample was requested be-
cause no conclusive outcome could be made. A follow-up
serum sample was received from 168/454 (37.0%) patients.
Serologic analysis of these follow-up serum samples yielded
the diagnoses of acute Q fever in 32 patients, no acute Q
fever in 133 patients, past resolved Q fever in 1 patient, and
an inconclusive outcome in 2 patients. In 11 of the 32 pa-
tients with acute Q fever diagnosed on the follow-up serum
sample, the diagnosis was missed in the first serum sample
despite the fact that PCR had been performed in addition to
MII screen. Q fever diagnostics were considered inconclu-
sive in the 286 patients in whom a follow-up serum sample
was not received. In 123/669 (18.4%) patients with a nega-
tive MII screen, the first serum sample was obtained 14
days after onset of disease and these patients were consid-
ered not to have acute Q fever. However, unrequested fol-
low-up serum samples from 26 patients in this group were
received. Serologic analysis of these follow-up serum sam-
ples confirmed the diagnosis of no acute Q fever in 24
patients but yielded the diagnosis of acute Q fever in 2
patients. In these two patients, the first serum samples had
been received 22 and 23 days after the onset of disease, with
follow-up serum samples received at 42 and 145 days, re-
spectively.
The date of onset of disease was available for 65/130
(50.0%) patients with a positive or borderline positive MII
screen in the first serum sample and an outcome of acute Q
fever. The number of days from onset of disease to acqui-
sition of the first serum sample in this group was 17  15
days (mean  standard deviation [SD]). In the group of
patients with a negative MII screen and an outcome of acute
Q fever, the date of onset of disease was available for 84/126
(66.7%) patients. The number of days from onset of disease
to acquisition of the first serum sample in this group was
significantly lower (P  0.01), being 5  4 days.
In all, the diagnosis of acute Q fever was made solely on
the first serum sample in 197/256 (77.0%) patients in whom
the diagnosis was eventually made. In 103 patients, a posi-
tive PCR analysis on the first serum sample contributed to
this diagnosis.
Inconsistency with the diagnostic algorithm was observed
for 27/825 (3.3%) patients. Mainly, nonadherence to the
flowchart resulted from misinterpretation of the diagnostic
algorithm or miscalculation of the number of days following
onset of disease. Other causes for nonadherence to the
flowchart were personal requests by treating physicians for
additional diagnostics, for instance because of special situ-
ations like pregnancy.
Outcome of additional PCR analysis. In all, we identified
147 patients with an MII screen-negative first serum sample
who had been referred by a family physician without infor-
mation on date of onset of disease and for whom the re-
quested follow-up serum sample was not received. For these
patients, the diagnostic algorithm did not allow for PCR
analysis on first serum samples. In the context of the eval-
uation of the diagnostic algorithm, PCR analysis was per-
formed retrospectively on 145 of these 147 serum samples
(two samples had insufficient volume for PCR analysis). A
positive PCR result was obtained in 11 serum samples. Thus,
the total number of patients in this cohort in whom the
diagnosis of acute Q fever was made either prospectively or
retrospectively was 267/825 (32.4%) patients.
DISCUSSION
Laboratory diagnosis of acute Q fever is important be-
cause of the atypical clinical presentation of the disease, its
requirement of specific antibiotic treatment, and the needs
for follow-up of the development of chronic disease, out-
break surveillance, and response in case of bioterrorist at-
tack (2, 6). The microbiological diagnostic facilities of the
JBH, which lies in the center of the epidemic area, had been
confronted with an explosive increase in diagnostic requests
for acute Q fever since the start of the epidemic in 2007. In
2009, the diagnostic demands on our laboratory were even
further increased as a result of the foreseen influenza A
(H1N1) pandemic. These factors urged us to implement a
diagnostic algorithm that provided accurate, fast, cost-effec-
tive, and standardized diagnostics for acute Q fever in an
outbreak setting.
Before May 2009, IFA had been the cornerstone of Q
fever diagnostics in the JBH. An important drawback to
serological diagnosis of acute Q fever, however, is the lag
phase in antibody response following infection. Previously,
we reported that real-time PCR on serum samples is a useful
approach to diagnose acute Q fever before development of
the antibody response (6). Specific drawbacks to IFA in-
clude the facts that it is time-consuming, nonautomated,
expensive, and subject to interobserver variability. Introduc-
tion of the MII screen on an automated ELISA processing
system was expected to significantly reduce the number of
IFA tests performed and overcome the specific drawbacks of
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IFA. A diagnostic algorithm implementing both PCR and
MII screen was implemented on 1 May 2009.
Evaluation of the outcome of the diagnostic algorithm in
patients referred in a 17-day period in the peak of the 2009
epidemic revealed that introduction of the MII screen re-
sulted in a reduction of IFA tests performed on first serum
samples by more than 80%. In addition, PCR of the first
serum samples contributed to the diagnosis of acute Q fever
in 92 patients with a negative MII screen and in 11 patients
with a positive MII screen. The diagnosis of acute Q fever
was made solely on the first serum sample in 77.0% of
patients in whom this diagnosis was eventually made. These
results do not take into account the 11 patients referred by
family physicians without information on the date of onset
of disease and a negative MII screen for whom retrospective
PCR analysis was positive. One could argue for the perfor-
mance of PCR as the sole test on all first serum samples.
However, C. burnetii DNA rapidly becomes undetectable in
serum as the serological response develops (6). Extrapola-
tion of reported rates of PCR positivity for specific serologic
profiles to the group of 94 patients with positive MII screens
and subsequent positive IFAs on the first serum sample
indicates that PCR—if performed—would presumably have
been positive in 8 patients and negative in 86 patients. Thus,
the performance of PCR as the sole test would have pre-
sumably resulted in a missed diagnosis of acute Q fever on
the first serum sample in 86 patients where our diagnostic
algorithm did allow for this diagnosis.
Eleven patients were identified in whom the diagnosis of
acute Q fever was initially missed on the first serum sample
despite the fact that both MII screen and PCR had been
performed. Our diagnostic algorithm did not allow for PCR
and IFA (the latter being considered the gold standard) to
be performed on all samples, making it not possible to
calculate sensitivities and specificities based on this study.
However, in a separate direct comparison to IFA, we ob-
served a sensitivity of 85.7% for the MII screen (J.C.E.
Meekelenkamp, unpublished data). In addition, PCR has a
reported sensitivity of 98.0% in a retrospective analysis on
selected seronegative serum samples (6). Thus, both tests
have some limitations in sensitivity that might account for
missed diagnosis of acute Q fever on first serum samples.
Furthermore, it cannot be excluded that there is a window
period following initial PCR positivity in which C. burnetii
DNA has disappeared but IgM antibodies to phase II anti-
gens have not yet appeared.
Cross-reactivity (false positivity) was documented in six pa-
tients with a positive MII screen but could not be excluded in
18 patients with a positive MII screen but no conclusive out-
come of Q fever diagnostics because a requested follow-up
serum sample was not received. In a separate direct compari-
son to IFA, we observed a specificity of 97.6% for the MII
screen (Meekelenkamp, unpublished). Cross-reactivity in C.
burnetii antibody tests has also been documented by others (4).
For that reason, serological evidence of acute Q fever was
defined in our laboratory as the presence of both IgM and IgG
antibodies to phase II antigens as detected by IFA.
ELISA and IFA have been reported to detect seroconver-
sion 10 to 15 days postinfection (4). Therefore, the diagnostic
algorithm considered patients with serum samples obtained
14 days after onset of disease and a negative MII screen not
to have acute Q fever. Consequently, follow-up serum samples
were not requested from these patients. In 26 patients, how-
ever, an unrequested follow-up serum sample was received,
and serologic analysis revealed acute Q fever in 2 of those
patients. Although it cannot be excluded that in both patients
seroconversion resulted from (asymptomatic) infection ac-
quired after referral of the first serum sample, it also cannot be
excluded that seroconversion occurred more than 3 weeks
postinfection. These and similar observations not part of this
evaluation have subsequently led to a change in the diagnostic
algorithm: follow-up serum samples are now requested from
all patients with a negative MII screen in a first serum sample
received 28 days after onset of disease.
Hampering the overall outcome of Q fever diagnostics, but
unrelated to the intrinsic usefulness of the diagnostic algo-
rithm, were the facts that the date of onset of disease was not
provided in more than half of the referrals and the requested
follow-up serum samples were not received from a high num-
ber of patients. Hospital physicians did not provide the date of
onset of disease in more than three of four referrals. It was
anticipated that they would be less accurate in providing this
date, which was one of the reasons that the diagnostic algo-
rithm allowed for PCR to be performed on all MII screen-
negative first serum samples referred by hospital physicians
without information on the date of onset of disease. Moreover,
we reasoned that hospitalized patients with acute Q fever
would have a more severe disease course than nonhospitalized
patients, justifying an additional PCR test on the first serum
sample even if the date of onset of disease was not provided.
Allowing PCR on the 94 MII screen-negative first serum sam-
ples referred by hospital physicians without information on the
date of onset of disease resulted in the diagnosis of acute Q
fever in 18.1% of these patients. In cases of MII screen-nega-
tive patients referred by family physicians without information
on the onset of disease, it was anticipated that the disease
course would be less severe, justifying a request for a follow-up
serum sample after 14 days. This approach was recently justi-
fied by a retrospective analysis that demonstrated that in 2009
95% of family physicians in the epidemic area would immedi-
ately start antibiotic treatment in case of suspected acute Q
fever without awaiting microbiological test results (3).
Requested follow-up serum samples were not received from
306 patients, leading to an inconclusive outcome. This implies
that cases of acute Q fever might have been missed. Indeed, a
retrospective PCR analysis on first serum samples revealed 11
cases of undiagnosed acute Q fever in patients for whom re-
quested follow-up serum samples were not referred. Therefore,
additional efforts will be made to inform both hospital and family
physicians of the importance of accurately providing the date of
onset of disease and referring requested follow-up serum sam-
ples.
Here, we show that introduction of a diagnostic algorithm
for acute Q fever in an outbreak setting resulted in increased
diagnostic yield from first serum samples, with a considerable
reduction in IFA tests performed. Both hospital and family
physicians need to be made more aware of the importance of
providing the date of onset of disease and referring requested
follow-up serum samples.
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